RecruitingNot ApplicableNCT05354778

HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study

Sponsor

Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo

Enrollment

180 participants

Start Date

Oct 16, 2022

Study Type

INTERVENTIONAL

Conditions

Ventilator associated pneumonia Healthcare-Associated Pneumonia

Summary

The use of corticosteroids in patients with severe community pneumonia, bacterial infection which kills lots of patients around the world, reduces the mortality of this infection. However, there are no studies with this type of drug regarding hospital-acquired pneumonia. This is the first multicenter randomized trial to test hydrocortisone plus standard therapy in critical care patients with nosocomial pneumonia. This intervention is inexpensive and may improve the outcome of those patients, besides having an acceptable side effects profile.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Hydrocortisone and a drug called Placebo for people with healthcare-associated pneumonia and ventilator associated pneumonia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.